24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT)

被引：0
|
作者：
Mease, PJ
Choy, EHS
Gladman, DD
Ritchlin, CT
Ruderman, EM
Steinfeld, SD
Weinberg, MA
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Univ London Kings Coll, London WC2R 2LS, England
[3] Univ Toronto, Toronto, ON, Canada
[4] Univ Rochester, Sch Med & Dent, Rochester, NY USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Erasme Univ Hosp, B-1070 Brussels, Belgium
[7] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
RHEUMATOLOGY | 2005年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP5
引用
收藏
页码：I3 / I3
页数：1
相关论文
共 50 条
  • [21] Adalimumab treatment effects on quality of life in patients with psoriatic arthritis: Results from adept
    Gladman, DD
    Mease, PJ
    Emery, R
    Wellborne, F
    Combe, B
    Weinberg, MA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 317 - 317
  • [22] TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE ULTIMATE STUDY
    D'Agostino, M. A.
    Conaghan, P. G.
    Gaillez, C.
    Boers, M.
    Naredo, E.
    Carron, P.
    Hanova, P.
    Cazenave, T.
    Bakewell, C.
    Duggan, A. M.
    Goyanka, P.
    Schett, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : 1160 - 1161
  • [23] Adalimumab is effective against skin and joint disease in psoriatic arthritis patients: 48-week results of ADEPT
    Mease, P. J.
    Gladman, D. D.
    Ritchlin, C. T.
    Ruderman, E. M.
    Choy, E. H. S.
    Steinfield, S. D.
    Sharp, J. T.
    Ory, P.
    Wang, H.
    Sasso, E.
    RHEUMATOLOGY, 2006, 45 : I68 - I69
  • [24] Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
    Cohen, Stanley
    Fiechtner, Justus
    Mease, Philip
    Kaine, Jeffrey
    Kavanaugh, Arthur
    Cheng, Yi-Lin
    Chou, Claire
    Cheng, Ting-Ying
    Lin, Shih-Yao
    Genovese, Mark
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [25] Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain
    Orbai, Ana-Maria
    Ballerini, Rocco
    Chou, Richard C.
    Rozzo, Stephen
    Mendelsohn, Alan
    Espinoza, Luis R.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [26] Tildrakizumab efficacy for psoriatic arthritis: 24-week analysis of swollen and tender joint counts and pain
    Espinoza, Luis R.
    Ballerini, Rocco
    Chou, Richard
    Rozzo, Stephen J.
    Mendelsohn, Alan M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB166 - AB166
  • [27] Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
    Kavanaugh, AF
    Ritchlin, CT
    Malaise, MG
    Wordsworth, P
    Birbara, CA
    Weinberg, MA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 325 - 325
  • [28] EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 24 IN BIOLOGIC EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SUMMARY RESULTS
    Marzo-Ortega, Helena
    Meroni, Pierluigi
    Galindez-Agirregoikoa, Eva
    Behrens, Frank
    Bradley, Andrew J.
    Leage, Soyi Liu
    Garcia, Miriam
    Sapin, Christophe
    Ho, Ji Chen
    Constantin, Arnaud
    Hall, Stephen
    RHEUMATOLOGY, 2018, 57
  • [29] SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS: A 24-WEEK, DOUBLE-BLIND, TRIAL
    McInnes, I.
    Sieper, J.
    Braun, J.
    Emery, P.
    van der Heijde, D.
    Isaacs, J.
    Dahmen, G.
    Wollenhaupt, J.
    Schulze-Koops, H.
    Gsteiger, S.
    Bertolino, A. P.
    Hueber, W.
    Tak, P. P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : 619 - 619
  • [30] EFFICACY AND SAFETY OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDs: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 TRIAL
    Kristensen, L. E.
    Keiserman, M.
    Papp, K.
    Mccasland, L.
    White, D.
    Barcomb, L.
    Lu, W.
    Wang, Z.
    Soliman, A. M.
    Eldred, A.
    Behrens, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1315 - 1316
12345